All In Biotech

Drug Trial Radar · NCT00123461

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).

Last checked: Nov 19, 2026Latest source record: May 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 2005

Primary completion

Oct 2007

Study completion Oct 2007

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jul 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.

Conditions

  • Secondary Hyperparathyroidism
  • Renal Failure
  • Chronic Renal Insufficiency

Interventions

  • Hectorol (doxercalciferol capsules), 0.5mcgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Laboratory measurement of intact parathyroid hormone (iPTH)Time frame: 6 months

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • AKDHC Medical Research Services

    Phoenix, Arizona

  • UCLA Diabetes Reseach Center

    Alhambra, California

  • Apex Research of Riverside

    Riverside, California

  • George Washington University Hospital

    Washington D.C., District of Columbia

  • Discovery Medical Research Group

    Ocala, Florida

  • Nephrology Associates

    Palm Beach Gardens, Florida

  • Georgia Kidney Associates, Inc.

    Marietta, Georgia

  • Michigan Kidney Consultants, P.C.

    Pontiac, Michigan

  • Twin Cities Clinical Research

    Brooklyn Center, Minnesota

  • University of Rochester Medical Center

    Rochester, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Wake Nephrology Associates, PA

    Raleigh, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Altru Health System Research Center

    Grand Forks, North Dakota

  • DaVita Lewiston Dialysis Center

    Lewiston, Pennsylvania

  • Temple University

    Philadelphia, Pennsylvania

  • Virginia Commonwealth University

    Richmond, Virginia

  • Instituto Renal del Este

    Caguas, Puerto Rico

  • Jose Cangiano, MD

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.